Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients

Stopped Sponsor decision based on slow recruitment and new emerging drug combinations

Conditions

• Carcinoma, Non-Small-Cell Lung

Interventions

• BIOLOGICAL: EGF Vaccine

Sponsor

Bioven Europe